{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:33:33Z","timestamp":1790699613281,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Swissmedic 4.0"},{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40264-023-01319-y","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T04:02:41Z","timestamp":1687147361000},"page":"753-763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Hospitalisations Related to Adverse Drug Reactions in Switzerland in 2012\u20132019: Characteristics, In-Hospital Mortality, and Spontaneous Reporting Rate"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-2480","authenticated-orcid":false,"given":"Patrick E.","family":"Beeler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-3843","authenticated-orcid":false,"given":"Thomas","family":"Stammschulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-0416","authenticated-orcid":false,"given":"Holger","family":"Dressel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"1319_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s40264-016-0444-7","volume":"39","author":"MT Angamo","year":"2016","unstructured":"Angamo MT, Chalmers L, Curtain CM, Bereznicki LRE. Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf. 2016;39:847\u201357.","journal-title":"Drug Saf"},{"key":"1319_CR2","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.4103\/0976-500X.120957","volume":"4","author":"J Sultana","year":"2013","unstructured":"Sultana J, Cutroneo P, Trifir\u00f2 G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4:S73-77.","journal-title":"J Pharmacol Pharmacother"},{"key":"1319_CR3","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/pds.2118","volume":"20","author":"D Rottenkolber","year":"2011","unstructured":"Rottenkolber D, Schmiedl S, Rottenkolber M, Farker K, Salj\u00e9 K, Mueller S, et\u00a0al. Adverse drug reactions in Germany: direct costs of internal medicine hospitalizations. Pharmacoepidemiol Drug Saf. 2011;20:626\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1319_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0953-6205(01)00159-5","volume":"12","author":"J-B Wasserfallen","year":"2001","unstructured":"Wasserfallen J-B, Livio F, Buclin T, Tillet L, Yersin B, Biollaz J. Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med. 2001;12:442\u20137.","journal-title":"Eur J Intern Med"},{"key":"1319_CR5","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00228-016-2170-6","volume":"73","author":"NS Patel","year":"2017","unstructured":"Patel NS, Patel TK, Patel PB, Naik VN, Tripathi CB. Hospitalizations due to preventable adverse reactions-a systematic review. Eur J Clin Pharmacol. 2017;73:385\u201398.","journal-title":"Eur J Clin Pharmacol"},{"key":"1319_CR6","unstructured":"Guideline IHT. Post-approval safety data management: definitions and standards for expedited reporting E2D. Eur Union Int Conf Harmon. 2003."},{"key":"1319_CR7","unstructured":"Swissmedic 2019 \u00a9 Copyright. Reporting of suspected adverse drug reactions by patients [Internet]. https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/marktueberwachung\/pharmacovigilance\/patienten-innen.html. Cited 5 June 2022."},{"key":"1319_CR8","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1046\/j.1365-2125.2000.00132.x","volume":"49","author":"K Fattinger","year":"2000","unstructured":"Fattinger K, Roos M, Verg\u00e8res P, Holenstein C, Kind B, Masche U, et\u00a0al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49:158\u201367.","journal-title":"Br J Clin Pharmacol"},{"key":"1319_CR9","first-page":"664","volume":"134","author":"B Hardmeier","year":"2004","unstructured":"Hardmeier B, Braunschweig S, Cavallaro M, Roos M, Pauli-Magnus C, Giger M, et\u00a0al. Adverse drug events caused by medication errors in medical inpatients. Swiss Med Wkly. 2004;134:664\u201370.","journal-title":"Swiss Med Wkly"},{"key":"1319_CR10","unstructured":"SR 812.21\u2014Federal Act of 15 December 2000 on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA) [Internet]. https:\/\/www.fedlex.admin.ch\/eli\/cc\/2001\/422\/en. Cited 5 June 2022."},{"key":"1319_CR11","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2021.20400","volume":"151","author":"S Banholzer","year":"2021","unstructured":"Banholzer S, Dunkelmann L, Haschke M, Derungs A, Exadaktylos A, Kr\u00e4henb\u00fchl S, et\u00a0al. Retrospective analysis of adverse drug reactions leading to short-term emergency hospital readmission. Swiss Med Wkly. 2021;151: w20400.","journal-title":"Swiss Med Wkly"},{"key":"1319_CR12","unstructured":"Statistik B f\u00fcr. Medizinische Statistik der Krankenh\u00e4user [Internet]. https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/gesundheit\/erhebungen\/ms.html. Cited 26 Nov 2021."},{"key":"1319_CR13","unstructured":"ICD-10 Version:2019 [Internet]. https:\/\/icd.who.int\/browse10\/2019\/en. Cited 14 Nov 2021."},{"key":"1319_CR14","unstructured":"Statistik B f\u00fcr. Medizinische Statistik der Krankenh\u00e4user - Variablen der Medizinischen Statistik. Spezifikationen g\u00fcltig ab 1.1.2019 | Publikation [Internet]. Bundesamt F\u00fcr Stat. 2018. https:\/\/www.bfs.admin.ch\/asset\/de\/7066232. Cited 20 June 2022."},{"key":"1319_CR15","unstructured":"BfArM\u2014ICD-10-GM Version\u00a02022 [Internet]. https:\/\/www.dimdi.de\/static\/de\/klassifikationen\/icd\/icd-10-gm\/kode-suche\/htmlgm2022\/. Cited 14 June 2022."},{"key":"1319_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J DIJ Drug Inf Assoc. 2008;42:409\u201319.","journal-title":"Drug Inf J DIJ Drug Inf Assoc."},{"key":"1319_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et\u00a0al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLoS Med. 2015;12: e1001885.","journal-title":"PLoS Med"},{"key":"1319_CR18","unstructured":"WHO Meeting on International Drug Monitoring: the Role of National Centres (1971: Geneva S, Organization WH. International drug monitoring\u202f: the role of national centres , report of a WHO meeting [held in Geneva from 20 to 25 September 1971] [Internet]. World Health Organization; 1972. https:\/\/apps.who.int\/iris\/handle\/10665\/40968."},{"key":"1319_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7861\/clinmedicine.16-5-481","volume":"16","author":"JJ Coleman","year":"2016","unstructured":"Coleman JJ, Pontefract SK. Adverse drug reactions. Clin Med. 2016;16:481\u20135.","journal-title":"Clin Med"},{"key":"1319_CR20","unstructured":"Directive EU. 84\/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance. Directive 2001\/83\/EC on the Community code relating to medicinal products\u00a0\u2026; 2010."},{"key":"1319_CR21","unstructured":"Agency EM. Guideline on good pharmacovigilance practices (GVP)-Annex I-Definitions (Rev 4). Heads Med Agencies. 2017;1\u201333."},{"key":"1319_CR22","unstructured":"Statistik B f\u00fcr. Instrumente zur medizinischen Kodierung [Internet]. https:\/\/www.bfs.admin.ch\/bfs\/de\/home\/statistiken\/gesundheit\/nomenklaturen\/medkk\/instrumente-medizinische-kodierung.html. Cited 15 June 2022."},{"key":"1319_CR23","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/amiajnl-2013-002116","volume":"21","author":"CM Hohl","year":"2014","unstructured":"Hohl CM, Karpov A, Reddekopp L, Doyle-Waters M, Stausberg J. ICD-10 codes used to identify adverse drug events in administrative data: a systematic review. J Am Med Inform Assoc JAMIA. 2014;21:547\u201357.","journal-title":"J Am Med Inform Assoc JAMIA."},{"key":"1319_CR24","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et\u00a0al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130\u20139.","journal-title":"Med Care"},{"key":"1319_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40266-017-0490-6","volume":"34","author":"N Parameswaran Nair","year":"2017","unstructured":"Parameswaran Nair N, Chalmers L, Bereznicki BJ, Curtain CM, Bereznicki LR. Repeat adverse drug reaction-related hospital admissions in elderly Australians: a retrospective study at the Royal Hobart Hospital. Drugs Aging. 2017;34:777\u201383.","journal-title":"Drugs Aging"},{"key":"1319_CR26","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s00228-017-2225-3","volume":"73","author":"TJ Oscanoa","year":"2017","unstructured":"Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol. 2017;73:759\u201370.","journal-title":"Eur J Clin Pharmacol."},{"key":"1319_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2165\/11319030-000000000-00000","volume":"33","author":"AJ Leendertse","year":"2010","unstructured":"Leendertse AJ, Visser D, Egberts ACG, van den Bemt PMLA. The relationship between study characteristics and the prevalence of medication-related hospitalizations: a literature review and novel analysis. Drug Saf. 2010;33:233\u201344.","journal-title":"Drug Saf"},{"key":"1319_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40264-015-0281-0","volume":"38","author":"JC Bouvy","year":"2015","unstructured":"Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38:437\u201353.","journal-title":"Drug Saf"},{"key":"1319_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1345\/aph.1L037","volume":"42","author":"C Kongkaew","year":"2008","unstructured":"Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42:1017\u201325.","journal-title":"Ann Pharmacother"},{"key":"1319_CR30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00228-020-03043-3","volume":"77","author":"M Kauppila","year":"2021","unstructured":"Kauppila M, Backman JT, Niemi M, Lapatto-Reiniluoto O. Incidence, preventability, and causality of adverse drug reactions at a university hospital emergency department. Eur J Clin Pharmacol. 2021;77:643\u201350.","journal-title":"Eur J Clin Pharmacol"},{"key":"1319_CR31","doi-asserted-by":"crossref","unstructured":"Hooijman MF, Martinez-De la Torre A, Weiler S, Burden AM. Opioid sales and opioid-related poisonings in Switzerland: a descriptive population-based time-series analysis. Lancet Reg Health Eur. 2022;20:100437.","DOI":"10.1016\/j.lanepe.2022.100437"},{"key":"1319_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et\u00a0al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15\u20139.","journal-title":"BMJ"},{"key":"1319_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00228-018-2441-5","volume":"74","author":"TK Patel","year":"2018","unstructured":"Patel TK, Patel PB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol. 2018;74:819\u201332.","journal-title":"Eur J Clin Pharmacol"},{"key":"1319_CR34","doi-asserted-by":"crossref","unstructured":"Murdaugh L. Adverse drug reaction reporting. Competence Tools Health Syst Pharm. 2017;545\u201356.","DOI":"10.37573\/9781585284030.040"},{"key":"1319_CR35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.2215\/CJN.01030120","volume":"15","author":"SM Laville","year":"2020","unstructured":"Laville SM, Gras-Champel V, Moragny J, Metzger M, Jacquelinet C, Combe C, et\u00a0al. Adverse drug reactions in patients with CKD. Clin J Am Soc Nephrol CJASN. 2020;15:1090\u2013102.","journal-title":"Clin J Am Soc Nephrol CJASN."},{"key":"1319_CR36","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions\u202f: a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"1319_CR37","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/bmj.320.7241.1036","volume":"320","author":"P Pouyanne","year":"2000","unstructured":"Pouyanne P, Haramburu F, Imbs JL, B\u00e9gaud B. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study. BMJ. 2000;320:1036.","journal-title":"BMJ"},{"key":"1319_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1365-2125.1992.tb04001.x","volume":"33","author":"J Hallas","year":"1992","unstructured":"Hallas J, Gram LF, Grodum E, Damsbo N, Br\u00f8sen K, Haghfelt T, et\u00a0al. Drug related admissions to medical wards. Br J Clin Pharmacol. 1992;33:61\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"1319_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105388","volume":"140","author":"S Thakkar","year":"2023","unstructured":"Thakkar S, Slikker W, Yiannas F, Silva P, Blais B, Chng KR, et\u00a0al. Artificial intelligence and real-world data for drug and food safety\u2014a regulatory science perspective. Regul Toxicol Pharmacol. 2023;140: 105388.","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01319-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01319-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T11:21:19Z","timestamp":1689247279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01319-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1319"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01319-y","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"9 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by University of Zurich. This study was supported by the Swissmedic 4.0 initiative. The funding source played no role in the design and conduct of this study; the collection, management, analysis of the data or the interpretation of the results; or the review and approval of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors PEB, TS, and HD have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present investigation used completely anonymous data and conformed with the Swiss law and the ethical review and research policies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Supplementary tables are available online with this publication. The data used in this study may be obtained from third parties but cannot be shared by the authors due to licensing issues and data protection requirements.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The code of this study is available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"PEB conceived and designed the study, processed the data and performed the statistical analyses. All authors interpreted data. PEB drafted the work with TS and HD critically commenting on it. All authors approved the final submitted version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}